Skip to main content
. 2010 Oct 25;55(1):184–189. doi: 10.1128/AAC.01078-10

FIG. 4.

FIG. 4.

Hepatic outcomes by length of therapy. An ALP CTC increase of >2 controlled for the FDA dosing group, a bilirubin level >5× the baseline controlled for FDA dosing group and initial bilirubin concentration, and an ALP level >3× the ULN controlled for FDA dosing group, initial ALP concentration, and mg/kg dose.